ReviewWorld journal of hepatology2025
Heart rate variability in the clinical assessment of patients with chronic liver disease.
Review in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autonomic dysfunction (AD) is frequently observed in cirrhotic patients and is associated with poor clinical outcomes and prognoses. Heart rate variability (HRV), a noninvasive tool for assessing autonomic nervous system balance, has been extensively studied in a variety of conditions, including chronic liver disease (CLD); however, no recent reviews have focused on its role in CLD. This article examines the mechanisms of AD in CLD and the foundation for HRV assessment, highlighting its diagnostic, prognostic, and therapeutic applications in CLD, including liver transplantation (LT). Changes in HRV, particularly in patients with cirrhotic complications, and its prognostic significance throughout the natural history of CLD are summarized. We show that HRV is consistently reduced in CLD patients, reflecting AD, and is inversely correlated with liver disease severity. Also, low HRV is associated with complications such as hepatic encephalopathy, ascites, and portal hypertension. Moreover, evidence indicates that reduced HRV is an independent risk factor for mortality and circulatory instability in CLD. Furthermore, treatment with beta-blockers and LT improves HRV, underscoring its potential role in patient management. While further studies are needed, HRV emerges as a promising tool for the comprehensive evaluation and clinical management of patients with CLD, offering insights into disease progression and therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.